PL2831261T3 - Sposób wytwarzania rekombinowanych białek o niskim poziomie DHNA (1,4-dihydroksy-2-naftoesanu) - Google Patents

Sposób wytwarzania rekombinowanych białek o niskim poziomie DHNA (1,4-dihydroksy-2-naftoesanu)

Info

Publication number
PL2831261T3
PL2831261T3 PL13713295T PL13713295T PL2831261T3 PL 2831261 T3 PL2831261 T3 PL 2831261T3 PL 13713295 T PL13713295 T PL 13713295T PL 13713295 T PL13713295 T PL 13713295T PL 2831261 T3 PL2831261 T3 PL 2831261T3
Authority
PL
Poland
Prior art keywords
dhna
naphthoate
dihydroxy
low levels
recombinant proteins
Prior art date
Application number
PL13713295T
Other languages
English (en)
Inventor
Michael W. Laird
Richard St. John
Jane V. GUNSON
Kim KALEAS
Deepa NADARAJAH
Rachel Adams
Bradley R. Snedecor
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL2831261T3 publication Critical patent/PL2831261T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/42—Means for regulation, monitoring, measurement or control, e.g. flow regulation of agitation speed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Sustainable Development (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL13713295T 2012-03-27 2013-03-14 Sposób wytwarzania rekombinowanych białek o niskim poziomie DHNA (1,4-dihydroksy-2-naftoesanu) PL2831261T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616297P 2012-03-27 2012-03-27
PCT/US2013/031383 WO2013148249A1 (en) 2012-03-27 2013-03-14 Improved harvest operations for recombinant proteins
EP13713295.7A EP2831261B1 (en) 2012-03-27 2013-03-14 Method for producing recombinant proteins with low levels of DHNA (1,4-dihydroxy-2-naphthoate)

Publications (1)

Publication Number Publication Date
PL2831261T3 true PL2831261T3 (pl) 2018-04-30

Family

ID=48040433

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13713295T PL2831261T3 (pl) 2012-03-27 2013-03-14 Sposób wytwarzania rekombinowanych białek o niskim poziomie DHNA (1,4-dihydroksy-2-naftoesanu)

Country Status (21)

Country Link
US (8) US20140080180A1 (pl)
EP (1) EP2831261B1 (pl)
JP (4) JP6225162B2 (pl)
KR (2) KR20200037425A (pl)
CN (2) CN104350156B (pl)
AR (2) AR090340A1 (pl)
AU (3) AU2013240280A1 (pl)
BR (1) BR112014023176B1 (pl)
CA (2) CA3086730A1 (pl)
ES (1) ES2654424T3 (pl)
HK (1) HK1207120A1 (pl)
HR (1) HRP20171966T1 (pl)
IL (1) IL234377B (pl)
MX (3) MX365947B (pl)
MY (1) MY171729A (pl)
PL (1) PL2831261T3 (pl)
RU (2) RU2636353C2 (pl)
SG (4) SG10201508420VA (pl)
SI (1) SI2831261T1 (pl)
WO (1) WO2013148249A1 (pl)
ZA (1) ZA201406434B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892820A1 (ru) 2016-06-10 2019-10-31 Способ стабилизации белков
TWI763732B (zh) 2016-11-07 2022-05-11 美商西雅圖遺傳學公司 工程化半胱胺酸帽之分佈
JP2021519298A (ja) * 2018-03-27 2021-08-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 紫外線シグナルを使用した力価のリアルタイムモニタリング
CN109725088B (zh) * 2019-03-16 2021-05-18 丁立平 一种测定豆芽中2-萘甲酸及其衍生物的气相色谱-质谱联用法
CN110305903B (zh) * 2019-07-31 2021-10-01 江苏璟泽生物医药有限公司 重组人促卵泡激素及其制备方法
CN113155776A (zh) * 2021-04-29 2021-07-23 华东交通大学 一种柑桔最佳采收期预测方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0602126B1 (en) 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
MX9602818A (es) 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
ES2183131T3 (es) 1996-01-23 2003-03-16 Genentech Inc Anticuerpos anti-cd18 utilizados contra el ictus cerebral.
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2272842C (en) 1996-11-27 2012-05-15 Genentech, Inc. Humanized anti-cd11a antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60039448D1 (de) 1999-10-29 2008-08-21 Genentech Inc Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
US6946271B2 (en) * 2000-09-20 2005-09-20 Degussa Ag Nucleotide sequences which code for the menE gene
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
CA2520052C (en) * 2003-03-26 2011-07-19 Meiji Dairies Corporation Method for stabilizing 1,4-dihydroxy-2-napthoic acid
ATE353969T1 (de) * 2003-08-13 2007-03-15 Sandoz Ag Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide
CN1914330B (zh) * 2004-02-04 2012-10-24 默沙东公司 通过大肠杆菌发酵大规模生产质粒dna的方法
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN101115832A (zh) * 2004-11-26 2008-01-30 协和发酵工业株式会社 工业上有用的微生物
WO2007130655A2 (en) * 2006-05-05 2007-11-15 Gangagen, Inc. Phage derived antimicrobial activities
JP5305615B2 (ja) * 2006-06-05 2013-10-02 株式会社Ａｄｅｋａ メナキノンの新規生合成経路に関与するタンパク質の遺伝子群を利用したメナキノンの製造方法
US20080125580A1 (en) * 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
KR20190140090A (ko) * 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101665798B (zh) * 2008-09-06 2012-11-21 浙江我武生物科技股份有限公司 一种制备重组人血清白蛋白与干扰素α融合蛋白的方法
CN101503470A (zh) * 2008-09-27 2009-08-12 上海交通大学 rhDSL重组蛋白及其制备方法
JP2010088387A (ja) * 2008-10-10 2010-04-22 Waseda Univ 放線菌内で目的タンパク質を誘導発現可能なプロモーター

Also Published As

Publication number Publication date
AU2017202484A1 (en) 2017-05-04
MY171729A (en) 2019-10-25
US20150225760A1 (en) 2015-08-13
CN104350156A (zh) 2015-02-11
SG10202007206WA (en) 2020-08-28
JP2019141049A (ja) 2019-08-29
EP2831261B1 (en) 2017-10-18
US20200199639A1 (en) 2020-06-25
AU2019226192A1 (en) 2019-09-26
CA3086730A1 (en) 2013-10-03
HK1207120A1 (en) 2016-01-22
US20180291411A1 (en) 2018-10-11
US20140080180A1 (en) 2014-03-20
SI2831261T1 (en) 2018-01-31
AR090340A1 (es) 2014-11-05
KR20140148392A (ko) 2014-12-31
JP6225162B2 (ja) 2017-11-01
MX2014011558A (es) 2014-11-14
MX2018007677A (es) 2020-11-12
JP2020202849A (ja) 2020-12-24
CA2866753A1 (en) 2013-10-03
MX365947B (es) 2019-06-19
CN109880867A (zh) 2019-06-14
RU2017139267A (ru) 2019-02-12
SG10201912877SA (en) 2020-02-27
US9765379B2 (en) 2017-09-19
CN104350156B (zh) 2019-04-02
AU2013240280A1 (en) 2014-10-16
HRP20171966T1 (hr) 2018-02-09
BR112014023176B1 (pt) 2021-09-28
US20210171997A1 (en) 2021-06-10
MX2019007032A (es) 2019-08-16
RU2636353C2 (ru) 2017-11-22
US20160130624A1 (en) 2016-05-12
EP2831261A1 (en) 2015-02-04
AR116615A2 (es) 2021-05-26
US20240158825A1 (en) 2024-05-16
ZA201406434B (en) 2017-08-30
AU2017202484B2 (en) 2019-06-13
SG11201406112TA (en) 2014-10-30
CA2866753C (en) 2020-09-22
JP2018046825A (ja) 2018-03-29
KR102096678B1 (ko) 2020-04-02
ES2654424T3 (es) 2018-02-13
JP2015512259A (ja) 2015-04-27
RU2014137554A (ru) 2016-05-20
US20230069966A1 (en) 2023-03-09
IL234377B (en) 2021-01-31
BR112014023176A2 (pt) 2017-06-20
WO2013148249A1 (en) 2013-10-03
SG10201508420VA (en) 2015-11-27
KR20200037425A (ko) 2020-04-08

Similar Documents

Publication Publication Date Title
HK1208875A1 (en) Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase e3
GB2518547B (en) Method for the preparation of high purity lignin
EP3050896A4 (en) Method for producing polypeptide heteromultimer
SG11201503646TA (en) Esterification of 2,5-furan-dicarboxylic acid
EP2804621A4 (en) GLUTAMINE-SAFE STABILIZED INSULIN ANALOG
EP3067367A4 (en) Method for purifying recombinant protein
HK1209790A1 (en) Method of producing recombinant iduronate-2-sulfatase -2-
PL2831261T3 (pl) Sposób wytwarzania rekombinowanych białek o niskim poziomie DHNA (1,4-dihydroksy-2-naftoesanu)
PL2688948T3 (pl) Sposób otrzymywania roztworu przyspieszacza
DK3444238T3 (da) Fremgangsmåde til fremstilling af difluormethylenforbindelser
BR112013012873A2 (pt) processo para preparar uma n, n-dialquiletanolamina
HK1198584A1 (en) Process for the preparation of travoprost
EP2832387A4 (en) MANUFACTURING METHOD FOR MEDICAL INSTRUMENT, MEDICAL INSTRUMENT
EP3022176B8 (en) Azacyclic constrained analogs of fty720
EP2768846A4 (en) METHODS OF PURIFYING ERYTHROPOIETIN ANALOGS HAVING A LOWER ISOELECTRIC POINT
EP3091002A4 (en) Method for producing 5-hydroxypiperidine-2-carboxylic acid
IL239328A0 (en) A continuous process for the production of (s)-2-acetyloxypropionate chloride
PL3269698T3 (pl) Sposób wytwarzania fluorowanych olefin
HK1202555A1 (en) Process for the manufacture of cyclic undecapeptides
IL235052A0 (en) A method for increasing the secretion of recombinant proteins
PL2886651T3 (pl) Sposób wytwarzania l-aminokwasu
EP2970056A4 (en) METHOD FOR PRODUCING FLUORIZED OLEFINS
HK1215436A1 (zh) 取代的 -甲基氨基甲酰基- -氟苯基氨基 四氫呋喃- -甲酸 變體 和其酯，其製備方法和用途
EP2910545A4 (en) PROCESS FOR PREPARING N, N-DIALKYLHOMOFARNESIC ACID AMID
CL2012003578A1 (es) Proceso para preparar compuestos derivados de acido gama-amino-delta-bifenil-alfa-metil-alcanoico; y compuestos derivados de acido gama-amino-delta-bifenil-alfa-metil-alcanoico.